Axiom Space-tested cancer drug advances to clinical trials

mission critical

A new cancer-fighting drug will move to clinical trials after being tested on Axiom's Ax-2 and Ax-3 missions. Photo courtesy Axiom Space.

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

From Your Site Articles
The Rice Business Plan Competition is back in person this year, and these are the 42 teams that will go head to head for investments and prizes. Photo courtesy of Rice University

Rice University's student startup competition names 42 teams to compete for over $1 million in prizes

ready to pitch

The Rice Alliance for Technology and Entrepreneurship and the Jones Graduate School of Business have announced the 42 student teams that will compete in the 2022 Rice Business Plan Competition, which returns to an in-person format on the Rice University campus in April.

Of the teams competing for more than $1 million in prizes and funding in this year's competition, six hail from Texas — two teams each from Rice University, University of Texas at Austin, and Texas A&M University. The student competitors represent 31 universities — including three from European universities. The 42 teams were narrowed down from over 400 applicants and divided into five categories: energy, cleantech and sustainability; life sciences and health care solutions; consumer products and services; hard tech; and digital enterprise.

This is the first in-person RBPC since 2019, and the university is ready to bring together the entrepreneurs and a community of over 250 judges, mentors, and investors to the competition.

“As we come out on the other side of a long and challenging two years, we're feeling a sense of renewal and energy as we look to the future and finding inspiration from the next generation of entrepreneurs who are building a better world,” says Catherine Santamaria, director of the RBPC, in a news release.

“This year's competition celebrates student founders with a strong sense of determination — founders who are ready to adapt, build and grow companies that can change the future,” she continues. “We hope their participation will provide guidance and inspiration for our community.”

According to a news release, this year's RBPC Qualifier Competition, which narrowed down Rice's student teams that will compete in the official competition, saw the largest number of applicants, judges, and participants in the competition’s history. The Rice Alliance awarded a total of $5,000 in cash prizes to the top three teams from the internal qualifier: EpiFresh, Green Room and Anvil Diagnostics. From those three, Rice teams EpiFresh and Green Room received invitations to compete in the 2022 RBPC..

The full list of student teams that will be competing April 7 to 9 this year include:

  • Acorn Genetics from Northwestern University
  • Advanced Optronics from Carnegie Mellon University
  • Aethero Space from University of Missouri
  • AImirr from University of Chicago
  • AiroSolve from UCLA
  • Algeon Materials from UC San Diego
  • Anise Health from Harvard University
  • Beyond Silicon from Arizona State University
  • Bold Move Beverages from University of Texas at Austin
  • Diamante from University of Verona
  • EarthEn from Arizona State University
  • Empower Sleep from University of Pennsylvania
  • EpiFresh from Rice University
  • EpiSLS from University of Michigan
  • Green Room from Rice University
  • Horizon Health Solutions from University of Arkansas
  • Hoth Intelligence from Thomas Jefferson University
  • INIA Biosciences from Boston University
  • Invictus BCI from MIT
  • Invitris from Technical University of Munich (TUM)
  • KLAW Industries from Binghamton University
  • LIDROTEC from RWTH Aachen
  • Locus Lock from University of Texas at Austin
  • LymphaSense from Johns Hopkins University
  • Mallard Bay Outdoors from Louisiana State University
  • Mantel from MIT
  • Olera from Texas A&M University
  • OpenCell AI from Weill Cornell Medicine
  • OraFay from UCLA
  • Pareto from Stanford University
  • Photonect Interconnect Solutions from University of Rochester
  • PLAKK from McGill University
  • PneuTech from Johns Hopkins University
  • Rola from UC San Diego
  • RotorX from Georgia Tech
  • SimulatED from Carnegie Mellon University
  • SuChef from University of Pennsylvania
  • Symetric Finance from Fairfield University
  • Teale from Texas A&M University
  • Team Real Talk from University at Buffalo
  • TransCrypts from Harvard University
  • Woobie from Brigham Young University
Last year's awards had 54 student teams competing virtually, with over $1.4 million in cash and prizes awarded. Throughout RBPC's history, competitors have gone onto raise more than $3.57 billion in capital and more than 259 RBPC alumni have successfully launched their ventures. Forty RBPC startups that have had successful exits through acquisitions or trading on a public market, per the news release.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston doctor wins NIH grant to test virtual reality for ICU delirium

Virtual healing

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal.

While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU).

The five-year study will focus on older patients using mental stimulation techniques to reduce incidences of delirium. The award comes courtesy of the National Institute on Aging K76 Paul B. Beeson Emerging Leaders Career Development Award in Aging.

“As the population of older adults continues to grow, the need for effective, scalable interventions to prevent postoperative complications like delirium is more important than ever,” Faisal said in a news release.

ICU delirium is a serious condition that can lead to major complications and even death. Roughly 87 percent of patients who undergo major surgery involving intubation will experience some form of delirium coming out of anesthesia. Causes can range from infection to drug reactions. While many cases are mild, prolonged ICU delirium may prevent a patient from following medical advice or even cause them to hurt themselves.

Using VR games to treat delirium is a rapidly emerging and exciting branch of medicine. Studies show that VR games can help promote mental activity, memory and cognitive function. However, the full benefits are currently unknown as studies have been hampered by small patient populations.

Faisal believes that half of all ICU delirium cases are preventable through VR treatment. Currently, a general lack of knowledge and resources has been holding back the advancement of the treatment.

Hopefully, the work of Faisal in one of the busiest medical cities in the world can alleviate that problem as she spends the next half-decade plugging patients into games to aid in their healing.

New accelerator joins the Ion and more Houston innovation news to know

Trending News

Editor's note: The Houston innovation scene is buzzing with big news this month, from a new accelerator joining the fold at the Ion to pre-IPO funding and national expansion plans. Below are the five most-read InnovationMap stories from Feb. 1-15, 2026:

New accelerator for AI startups to launch at Houston's Ion this spring

The new AI Native Dual-Use Sports, Health & Wellness Accelerator is expected to launch in March. Photo courtesy of the Ion

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform. The AI Native Dual-Use Sports, Health & Wellness Accelerator is scheduled to formally launch in March. Continue reading.

10+ can't-miss Houston business and innovation events in February

From recurring monthly favorites to the return of annual celebrations and summits, here's what not to miss in February. Photo courtesy the Ion.

February may be a short month, but its event calendar isn’t. From recurring monthly favorites to the return of annual celebrations and summits, here are the Houston business and innovation events not to miss — and how to register. Continue reading.

Houston lab-test startup seeks $1M for nationwide expansion

Jim Gebhart, founder and CEO of TheLabCafe.com. Courtesy photo.

Health care industry veteran Jim Gebhart knew there had to be a better way for patients to access lab services, especially those with high health insurance deductibles or no insurance at all. Continue reading.

Houston wearable biosensing company closes $13M pre-IPO round

Wellysis is known for its continuous ECG/EKG monitor with AI reporting, known as the S-Patch. Photo via wellysis.com.

Wellysis, a Seoul, South Korea-headquartered wearable biosensing company with its U.S. subsidiary based in Houston, has closed a $13.5 million pre-IPO funding round and plans to expand its Texas operations. Continue reading. Continue reading.

Texas booms as No. 3 best state to start a business right now

Texas is rebounding in a report of the best states to start a business. Photo via Getty Images

High employment growth and advantageous entrepreneurship rates have led Texas into a triumphant No. 3 spot in WalletHub's ranking of "Best and Worst States to Start a Business" for 2026. Continue reading.

Houston scientists develop breakthrough AI-driven process to design, decode genetic circuits

biotech breakthrough

Researchers at Rice University have developed an innovative process that uses artificial intelligence to better understand complex genetic circuits.

A study, published in the journal Nature, shows how the new technique, known as “Combining Long- and Short-range Sequencing to Investigate Genetic Complexity,” or CLASSIC, can generate and test millions of DNA designs at the same time, which, according to Rice.

The work was led by Rice’s Caleb Bashor, deputy director for the Rice Synthetic Biology Institute and member of the Ken Kennedy Institute. Bashor has been working with Kshitij Rai and Ronan O’Connell, co-first authors on the study, on the CLASSIC for over four years, according to a news release.

“Our work is the first demonstration that you can use AI for designing these circuits,” Bashor said in the release.

Genetic circuits program cells to perform specific functions. Finding the circuit that matches a desired function or performance "can be like looking for a needle in a haystack," Bashor explained. This work looked to find a solution to this long-standing challenge in synthetic biology.

First, the team developed a library of proof-of-concept genetic circuits. It then pooled the circuits and inserted them into human cells. Next, they used long-read and short-read DNA sequencing to create "a master map" that linked each circuit to how it performed.

The data was then used to train AI and machine learning models to analyze circuits and make accurate predictions for how untested circuits might perform.

“We end up with measurements for a lot of the possible designs but not all of them, and that is where building the (machine learning) model comes in,” O’Connell explained in the release. “We use the data to train a model that can understand this landscape and predict things we were not able to generate data on.”

Ultimately, the researchers believe the circuit characterization and AI-driven understanding can speed up synthetic biology, lead to faster development of biotechnology and potentially support more cell-based therapy breakthroughs by shedding new light on how gene circuits behave, according to Rice.

“We think AI/ML-driven design is the future of synthetic biology,” Bashor added in the release. “As we collect more data using CLASSIC, we can train more complex models to make predictions for how to design even more sophisticated and useful cellular biotechnology.”

The team at Rice also worked with Pankaj Mehta’s group in the department of physics at Boston University and Todd Treangen’s group in Rice’s computer science department. Research was supported by the National Institutes of Health, Office of Naval Research, the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the American Heart Association, National Library of Medicine, the National Science Foundation, Rice’s Ken Kennedy Institute and the Rice Institute of Synthetic Biology.

James Collins, a biomedical engineer at MIT who helped establish synthetic biology as a field, added that CLASSIC is a new, defining milestone.

“Twenty-five years ago, those early circuits showed that we could program living cells, but they were built one at a time, each requiring months of tuning,” said Collins, who was one of the inventors of the toggle switch. “Bashor and colleagues have now delivered a transformative leap: CLASSIC brings high-throughput engineering to gene circuit design, allowing exploration of combinatorial spaces that were previously out of reach. Their platform doesn’t just accelerate the design-build-test-learn cycle; it redefines its scale, marking a new era of data-driven synthetic biology.”

View All Listings